Hansoh Pharmaceutical Group Co. Ltd. has obtained clinical trial clearance from China’s National Medical Products Administration (NMPA) for HS-10529 tablets.
Mutations in the oncogene KRAS are widespread in several human cancers, including pancreatic ductal adenocarcinomas (92%), colorectal carcinomas (49%) and lung adenocarcinomas (35%). These mutations hyperactivate various downstream signaling pathways, including the MAPK and PI3K/ AKT pathways. In KRAS-mutant tumors, both primary and acquired resistances are common.
AT-rich interactive domain-containing protein 1A (ARID1A) encodes a switch/sucrose nonfermentable (SWI/SNF) complex and is mutated in around 10% of colorectal cancers. ARID1A deficiency damages DNA damage repair increasing tumor mutation burden in ovarian and gastrointestinal cancers.
Kinoteck Therapeutics Co. Ltd. has disclosed Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Scientists at Southern University of Science and Technology in Shenzhen, China, have identified a new regulator of the mammalian target of rapamycin (mTOR) pathway associated with the growth of colorectal cancer.
Although radiotherapy is widely used in cancer treatment, its effects on the tumor microenvironment (TME) can be immunosuppressive as well as immunostimulatory. Fibroblast activation protein (FAP) is expressed by cancer-associated fibroblasts (CAFs) in several tumors, with higher levels linked to a weakened immune response to immune checkpoint blockade in patients.
RAS G12D is one of the most frequent mutations in RAS, and when it occurs, it leaves RAS in a permanently active state, causing the cell to proliferate uncontrollably. Examples of the so-called RAS-addicted cancers are colorectal cancer or pancreatic ductal adenocarcinoma.
Elevated expression of DHX9 has been reported in multiple cancer types and it is associated with poor prognosis. In a recently published study, researchers from Accent Therapeutics Inc. evaluated the role of DHX9 in cancer using the tool compound ATX-968, designed as a potent and selective small-molecule inhibitor of DHX9.
Io Biotech Aps has presented preclinical data regarding their Arg1-derived peptide cancer vaccine IO-112 as a potential immunotherapeutic that would allow controlling the tumor microenvironment.
Researchers from Tianjin University have published data regarding development and preclinical characterization of a new anti-PD-L1/CD40 bispecific antibody (BsAb), BA-4415, designed to activate CD40 signaling specifically in the context of PD-L1 while simultaneously blocking PD-1/PD-L1 signaling.
